title: Growth hormone therapy and scoliosis in patients with Prader-Willi syndrome.
abstract: Growth hormone (GH) therapy for short stature in patients with Prader-Willi syndrome (PWS) has started worldwide, and various favorable effects have been reported. However, the possibility of progression of scoliosis arises as a new problem of the GH therapy. In this study, we analyzed whether 72 patients who have been followed up in our hospital have such a problem. They included 46 males and 26 females (41 patients with the GH therapy and 31 without it) aged from one to 49 years. Consequently, 33 (45.8%) of 72 patients had scoliosis with the Cobb angle of >10 degrees. Twenty (48.8%) of forty-one patients who received a GH therapy and 13 (41.9%) of 31 patients without the therapy had scoliosis, the frequency of scoliosis between the two groups showing no statistical difference (P = 0.56). Height velocity of scoliotic and non-scoliotic patients during the first year of the therapy was 8.59 +/- 1.92 and 10.70 +/- 2.54 cm, respectively, showing a significant difference (P < 0.001). This shows that accelerated height velocity may not induce scoliosis. Comparison of starting age of a GH treatment revealed that non-scoliotic patients received the therapy earlier than scoliotic patients (P = 0.021). Among 20 scoliotic patients who received the GH therapy, the degree of scoliosis progressed during the therapy in six patients, improved in three and fluctuated in one. Many patients showed progression of scoliosis with age irrespective of the use of GH, and some patients improved their scoliosis during the GH therapy. These findings showed that a GH therapy increases height velocity of PWS patients but does not necessarily develop scoliosis, and early start of the therapy may not be an exacerbating factor of scoliosis.
authors.affiliation: Department of Pediatrics, Dokkyo University School of Medicine Koshigaya Hospital, Saitama, Japan. t-nagai@dokkyomed.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Nagai
authors.forename: K
authors.initials: K
authors.lastname: Obata
authors.forename: T
authors.initials: T
authors.lastname: Ogata
authors.forename: N
authors.initials: N
authors.lastname: Murakami
authors.forename: Y
authors.initials: Y
authors.lastname: Katada
authors.forename: A
authors.initials: A
authors.lastname: Yoshino
authors.forename: S
authors.initials: S
authors.lastname: Sakazume
authors.forename: Y
authors.initials: Y
authors.lastname: Tomita
authors.forename: R
authors.initials: R
authors.lastname: Sakuta
authors.forename: N
authors.initials: N
authors.lastname: Niikawa
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D013006:Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D008297:Male; D011218:Prader-Willi Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D011859:Radiography; D012600:Scoliosis / Q000150:complications* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D013006:Growth Hormone